Several other equities research analysts also recently weighed in on MDGN. Needham & Company LLC reaffirmed a buy rating and issued a $12.00 price objective on shares of Medgenics in a report on Tuesday, June 7th. JMP Securities reaffirmed a buy rating and issued a $13.00 price objective on shares of Medgenics in a report on Wednesday, June 8th.
Medgenics (NASDAQ:MDGN) traded down 1.08% during midday trading on Friday, reaching $5.48. 13,354 shares of the company were exchanged. Medgenics has a 52-week low of $3.09 and a 52-week high of $8.50. The stock’s market capitalization is $203.19 million. The firm’s 50-day moving average price is $5.56 and its 200 day moving average price is $5.34.
Medgenics (NASDAQ:MDGN) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.39. Equities analysts predict that Medgenics will post ($1.30) earnings per share for the current year.
Receive News & Ratings for Medgenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.